Serum Institute to start phase-2 trials of Oxford-AstraZeneca vaccine

Expects to complete trials by year-end

Pune's Serum Institute of India (SII) is all set to start phase-2 clinical trials of the Oxford University prime vaccine candidate (AZD-1222) developed in collaboration with British-Swedish pharma giant AstraZeneca. The institute expects to complete both, phase-2 and 3 trials in India by the end of this year. 

"This is because large-scale trials on over 10,000 healthy volunteers is being conducted by Oxford University in the UK and the primary data would be made available to the Indian regulator for review," said someone close to the development. By November, one can expect some conclusive data to be out, the person